Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
30858550
DOI
10.1038/s41375-019-0413-0
PII: 10.1038/s41375-019-0413-0
Knihovny.cz E-resources
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- Philadelphia Chromosome * MeSH
- Consensus MeSH
- Real-Time Polymerase Chain Reaction methods MeSH
- Humans MeSH
- RNA, Messenger analysis MeSH
- Neoplasm, Residual MeSH
- Practice Guidelines as Topic * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Fusion Proteins, bcr-abl MeSH
- BCR-ABL1 fusion protein, human MeSH Browser
- RNA, Messenger MeSH
Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. Standardised use of EAC primer/probe sets and of centrally prepared plasmid standards had the greatest impact on reducing interlaboratory variability. In QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log difference were 40/67 (60%) and 52/67 (78%) at 10-3 and 36/67 (53%) and 53/67 (79%) at 10-4BCR-ABL1/ABL1. Standardized RNA extraction, cDNA synthesis and cycler platforms did not improve results further, whereas stringent application of technical criteria for assay quality and uniform criteria for data interpretation and reporting were essential. We provide detailed laboratory recommendations for the standardized MRD analysis in routine diagnostic settings and in multicenter clinical trials for Ph + ALL.
3 Medizinische Klinik Medizinische Fakultät Mannheim der Universität Heidelberg Mannheim Germany
Abteilung für Hämatologie und internistische Onkologie Universität Leipzig Leipzig Germany
Azienda Ospedaliera Universitaria Federico 2 di Napoli Università Naples Italy
Center for Human Genetics University Hospital Leuven and KU Leuven Leuven Belgium
Childrens Cancer Research Institute Labdia Labordiagnostik and Medical University Vienna Austria
Department of Diagnostic Hematology Institute of Hematology and Transfusion Medicine Warsaw Poland
Department of Genetic Biochemistry Hopital Robert Debré Paris France
Department of Hematology Laboratory of Molecular Biology University La Sapienza Roma Italy
Department of Hematology Royal Free Campus University College London London United Kingdom
Department of Hematology University Hospital of Salamanca Salamanca Spain
Department of Immunology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands
Department of Immunology Genetics and Pathology Rudbeck Laboratory Uppsala University Uppsala Sweden
Department of Medicine Hematology Oncology Goethe University Frankfurt Germany
Department of Pathology The Norwegian Radium Hospital Oslo University Hospital Oslo Norway
Division of Hematology and Hemotherapy Medical School University of São Paulo São Paulo Brazil
Hematology and Bone Marrow Transplant Unit ASST Papa Giovanni XXIII Bergamo Italy
Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece
Hematology Department Jagiellonain University Krakow Krakow Poland
Imperial Molecular Pathology Centre for Hematology Imperial College London London UK
Institut für Biostatistik und Mathematische Modellierung Goethe Universität Frankfurt Germany
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS Meldola Italy
Kinderspital Zürich Onkologie Diagnostik Labor Zürich Switzerland
MLL Munich Leukemia Laboratory Max Lebsche Platz 31 Munich Germany
Pediatric Clinic University of Milan Bicocca San Gerardo Hospital Monza Italy
Pediatric Hematology Oncology Schneider Children's Medical Center of Israel Petah Tikva Israel
Regional Genetics Laboratory Birmingham Women´s NHS Foundation Trust Birmingham UK
School of Medicine Division of Cancer and Hematology Cardiff University Cardiff UK
TYKSLAB Laboratory of Molecular Genetics Turku University Hospital Turku Finland
References provided by Crossref.org
